|
KMID : 0605720110170020267
|
|
Journal of the Korean Society of Biological Therapies in Psychiatry
2011 Volume.17 No. 2 p.267 ~ p.274
|
|
|
Efficacy of Aripiprazole in Korean Schizophrenic Patients with Prominent Negative Symptoms : A 52-Week, Prospective, Open-Label Study
|
|
Kim Hye-Soo
Kim Sung-Nyun
Jang Joon-Hwan
kwon Jun-Soo
|
|
|
Abstract
|
|
|
Objectives: This study was done to evaluate the efficacy of aripiprazole in the schizophrenic patients with prominent negative symptoms.
Methods: This study was a prospective, multicenter, single-group, 52-week open study of patients with schizophrenia, schizophreniform disorder and schizoaffective disorder. A total of 300 Korean patients participated in the study. Among them, 39 patients with prominent negative symptoms were initially administered 15mg/day of aripiprazole for the first 2 weeks, and then treated with 10-30mg/day. The efficacy measures included the Positive and Negative Syndrome Scale(PANSS) total, positive and negative subscale scores, the Clinical Global Impression-Severity of Illness(CGI-S), and the CGI-Global improvements(CGI-I).
Results: The significant improvements were observed in all 3 PANSS parameters ; total(-35.72 ; p＜.0001), positive subscale(-7.41 ; p＜.0001), and negative subscale scores(-11.56 ; p＜.0001). The difference between positive and negative subscale scores was significantly decreased from baseline to week 52. CGI-S was also decreased (-1.67 ; p＜.0001), and 41.03% of patients appeared to respond according to CGI-I.
Conslusion: Aripiprazole may be as much efficacious against negative symptoms as positive symptoms in schizophrenia. This suggests the possibility clinicians can consider aripiprazole as a drug of choice in the chronic schizophrenic patients with prominent negative symptoms before trying switching other antipsychotics with clozapine.
|
|
|
KEYWORD
|
|
|
Aripiprazole, Schizophrenia, Negative symptoms, Efficacy, Long-term treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|